

## Original Research Article

### **Antioxidative Potential of Foetal Haemoglobin in Sickle Cell Disease**

#### **Abstract**

**Background:** Oxidative stress is a clinical condition in sickle cell disease (SCD) that results from increased production of reactive oxygen species (ROS). High Foetal haemoglobin (HbF) is beneficial in sickle cell disease due to its ability to resist polymerization with sickle haemoglobin. The aim of this study is to determine the anti-oxidative potential of HbF in subjects with SCD.

**Methods:** Whole blood was used for the determination of HbF concentration while serum was used for the assay of Glutathione peroxidase (GPx), Super-oxide dismutase (SOD), and malondialdehyde (MDA). Alkali denaturation method was used for the determination of HbF while spectrophotometric method was used to assay for the various oxidative stress markers.

**Results:** The concentrations of HbF and MDA were significantly higher in the case subjects compared to the normal subjects. A direct relationship was observed between GPx ( $r = 0.47$ ) and SOD ( $r = 0.46$ ) with HbF. However, an inverse relationship was observed between MDA with HbF ( $r = -0.33$ ), GPx ( $r = -0.18$ ) and SOD ( $r = -0.26$ ).

**Conclusion:** We conclude that HbF potentially associates with the antioxidant enzymes (GPx and SOD) to counteract the oxidative effect of ROS in SCD.

**Keywords:** Sickle cell disease, Foetal haemoglobin, Oxidative stress, lipid peroxidation, Glutathione peroxidase, Super oxide dismutase.

## INTRODUCTION

Despite years of intensive research, Sickle cell disease still remains a disease of public interest, accounting for significant number of deaths globally. <sup>(1)</sup> This genetic blood disorder is characterized by an abnormal haemoglobin (HbS) that results from a point mutation in which glutamine on position 6 of chromosome 11 which codes (β)-globin chain is replaced by valine. <sup>(2)</sup> The sickle haemoglobin (HbS) is responsible for all the clinical outcomes of the disorder including polymerization, vaso-occlusion and elevated rate of oxidative stress <sup>(3)</sup>.

Oxidative stress (OS) is a state where the production of reactive oxygen species overwhelms the body's anti-oxidant defence system <sup>(4)</sup>. Several factors including HbS polymerization, decreased antioxidants activity, chronic haemolysis and inflammation have been reported to be responsible for increasing the rate of OS in SCD. The effect of these processes is an increase in the rate of tissue destruction <sup>(5)</sup>.

Malondialdehyde (MDA) is one of the commonest marker used for the estimation of oxidative stress. MDA measures the level of lipid peroxidation and cellular damage caused by reactive oxygen species (Dalle-Donne *et al.*, 2006)<sup>(6)</sup>. Several studies have associated individuals with sickle cell diseases with elevated MDA concentrations and increased tissue destruction.<sup>(7 & 8)</sup>

To regulate the concentration of ROS produced in cells, antioxidants including superoxide dismutase and glutathione play crucial roles in defending the cells against oxidative stress generated by ROS. <sup>(9)</sup> In normal physiological state, the antioxidative defence system work synergistically to mop up any excess free radicals such as superoxide ions, hydroxide ions and hydrogen peroxide generated in the body. However, in pathological states such as SCD, the antioxidative defence system is overwhelm by ROS leading to oxidative stress <sup>(10)</sup>

Foetal haemoglobin, plays a beneficial role in SCD due to its ability to neutralize HbS polymerization <sup>(11 & 12)</sup>. Neonates and some adults with SCD experience a mild form of disease due to production of high concentration of HbF in their blood <sup>(13 & 14)</sup>. However, Sickle cell subjects from African countries including Nigeria have been reported to have a low concentration of this haemoglobin <sup>(15)</sup>. This study therefore is aimed at assessing the effect of foetal haemoglobin concentration from this population on oxidative stress in sickle cell subjects.

## **METHODOLOGY**

### **Subjects**

The study was made up of twenty-five (25) steady state sickle cell subjects and seventeen (17) normal subjects.

### **Inclusion and Exclusion Criteria**

The criteria for inclusion of the sickle cell subjects included adults from 18 years and above, subjects not on hydroxy urea treatment and have not received blood transmission three months from the date of study. For the control subjects only adults with no history of ill health were recruited for the study.

### **Sample collection and analysis**

About 4.0ml of venous blood obtained from the participants was used for analysis of all the biochemical parameters. Whole blood was used for foetal haemoglobin analysis while serum was used for the analysis of oxidative stress markers; Glutathione peroxidase (GPx), super-oxide-dismutase (SOD) and malondialdehyde (MDA). Alkali denaturation method was used for the determination of foetal haemoglobin concentration while spectrophotometric method was used for determination of the oxidative stress parameters.

### **Statistical analysis**

Statistical analysis was performed with SPSS (version 20). Descriptive data was reported as means and standard error while students T-test was used to compare the means between groups. Pearson's correlation test was used to perform correlation analysis. All statistical values within  $P < 0.05$  were regarded as significant.

## RESULTS

The concentration and activities of oxidative stress markers in sickle cell subjects and normal subjects were estimated (Table 1). The level of lipid peroxidation (MDA) in sickle cell subjects was significantly higher than in normal subjects ( $P=0.001$ ). Similarly, the Foetal haemoglobin concentration (HbF) of the sickle cell subjects was also significantly higher than the control subjects ( $P=0.001$ ). However, the activity of the anti-oxidant enzymes in subjects with sickle cell anaemia were lower than in the normal subjects.

**Table 1: Oxidative stress markers in Sickle and Normal Subjects.**

Biochemical markers	Sickle cell Subjects (25)	Normal subjects (17)	P-value
HbF (%)	5.36±0.58	2.49±0.39	0.001*
MDA (µmol/mL)	14.09±1.20	4.95±1.35	0.001*
GPx (mg/mL)	34.77±3.09	42.29±4.95	0.246
SOD (µ/mL)	35.18±3.53	41.37±6.75	0.425

\* significant at  $P < 0.05$

HbF: Foetal haemoglobin, MDA: Malondialdehyde, GPx: Glutathione peroxidase SOD: Super-oxide-dismutase,

The composition of the oxidative stress markers within the mean foetal haemoglobin concentration ( $HbF \leq 5$ ) and those outside the range ( $HbF \geq 5$ ) were estimated (Table 2). The level of lipid peroxidation (MDA) in subjects with  $HbF \leq 5$  was significantly higher than those with  $HbF \geq 5$ . However subjects with  $HbF \geq 5$  showed an insignificant increase in activity of GPx, and SOD compared to those with  $HbF \leq 5$ .

**Table 2: Classification of oxidative stress biomarkers based on Foetal haemoglobin concentration in sickle cell subjects**

Oxidative stress markers	HbF ≤ 5 (13)	HbF ≥ 5 (12)	P-value
MDA (µmol/mL)	16305.71±1272.02	11684.63±1914.01	0.05*
SOD (µ/mL)	30.24±4.07	40.54±5.67	0.15
GPx (mg/mL)	31.46±3.22	38.35±5.39	0.28

HbF: Foetal haemoglobin, MDA: Malondialdehyde, GPx: Glutathione peroxidase SOD: Super oxide dismutase, CAT: Catalase

The correlation between the antioxidant enzymes with foetal haemoglobin and malondialdehyde was assayed (Table 3). Foetal haemoglobin significantly correlated positively with GPx and SOD and inversely with MDA. GPx and SOD also correlated inversely with MDA.

**Table 3: Correlation between anti-oxidant enzymes with Foetal haemoglobin and Malondialdehyde in sickle cell subjects**

<b>Biochemical markers</b>	<b>r</b>	<b>P-value</b>
HbF-MDA	-0.333	0.104
HbF-SOD	0.464	0.020*
HbF-GPx	0.473	0.017*
MDA-Gpx	-0.184	0.378
MDA-SOD	-0.257	0.215

## DISCUSSION

This study was carried out to determine the anti-oxidative potential of foetal haemoglobin in subjects with sickle cell disease. Foetal haemoglobin has been defined as the best modulator of clinical severity in sickle cell disease because of its ability to resist HbS polymerization<sup>(16)</sup>. Twenty-five (25) steady state sickle cell subjects with an average age of 23.0 years participated in the study. Seventeen (17) normal age matched subjects were used as control for the study. The foetal haemoglobin concentration, concentration of oxidative stress markers of the study population and their relationship was assayed.

Sickle cell subjects had significantly higher foetal haemoglobin concentration compared to the normal subjects. This difference has been associated to genetic factors in sickle cell subjects capable of maintaining the expression of the haemoglobin into adulthood<sup>(17)</sup>. The level of expression of foetal haemoglobin has also been reported to vary between sickle cell subjects; with some having a higher expression while others having a relatively lower expression of the haemoglobin. This finding is in agreement with previous studies by Olaniyi *et al.*<sup>(18)</sup>, who reported a similar foetal haemoglobin concentration of 5.16% using the same method of assay.

The rate of lipid peroxidation (MDA) in Sickle cell subjects was also significantly higher than in the normal subjects. The elevation in lipid peroxidation in sickle cell subjects has been associated with high concentration of reactive oxygen species (ROS) produced from processes including HbS-polymerization, haemolysis and ischemic reperfusion<sup>(19)</sup>. This observation is in agreement with the studies of Nader *et al.*<sup>(20)</sup>, Okorie *et al.*<sup>(21)</sup> and Afolayan *et al.*<sup>(5)</sup>, who also observed a significantly higher levels of MDA in sickle cell subjects compared to normal subjects.

The activities of glutathione peroxidase and super oxide dismutase (anti-oxidative enzymes) were lower in sickle cell subjects compared to normal subjects. The reduced activity of these enzyme is associated to the high amount of ROS generated in sickle cell subjects. At this rate, the expression of anti-oxidative enzymes can barely keep up with the elevated amount of ROS resulting in reduced expression of the enzymes<sup>(22)</sup>. Previous studies by Biswal *et al.*<sup>(23)</sup>, reported a similar finding. However, unlike the current study, they reported a significant difference in the antioxidant activities of the enzymes in the study population.

A comparison of the concentration of GPx, SOD and MDA in different HbF concentrations revealed a significant elevation of MDA in subjects with HbF $\leq$ 5% compared to those with HbF $>$ 5%. This observation suggests the beneficial role of higher HbF concentration against cellular damages caused by lipid peroxidation<sup>(24)</sup>. Conversely, the activities of GPx and SOD was slightly higher in subjects with HbF $>$ 5% than those with HbF $\leq$ 5%. This difference suggest that the foetal haemoglobin concentration plays a role in determining the concentration of anti-oxidative enzymes in sickle cell disease. however, more studies are needed to verify this finding.

The analysis of the association between HbF and the oxidative stress markers reveals that HbF significantly correlates with GPx and SOD while MDA inversely correlates with HbF. This observation suggests that the anti-oxidative properties of GPx and SOD is increased when the HbF is increased while the lipid peroxidation seems to prevail when the HbF concentration is low. Furthermore, the correlation between MDA with GPx and SOD revealed an inverse relationship. This finding further stress the role of GPx and SOD as antagonists of lipid peroxidation (MDA). Previous studies by Lia *et al.*<sup>(25)</sup> and Zhu *et al.*<sup>(26)</sup> have linked erythroid-derived necrosis factor-2 (NRF2) as a stimulant for the production of both antioxidant proteins and HbF in sickle cell disease. Hence, there is a possibility for individuals with higher expression of NRF2 to have higher expression of HbF, GPx and SOD.

## **Conclusion**

The findings of this study suggest that foetal haemoglobin potentially associates with anti-oxidant enzymes to counter the effect of oxidative stress produced by reactive oxygen species in subjects with sickle cell disease.

## **Ethical Approval**

The study protocol was approved by the Ethical and Health Committee of the Institution (Federal Teaching Hospital Abakaliki, Ebonyi state).

## **Consent**

As per international standard or university standard, Participants' written consent has been collected and preserved by the author(s).

UNDER PEER REVIEW

## REFERENCE

1. Piel FB, Steinberg MH, Rees DC. Sickle cell disease. *N Engl J Med* 2017;376(16):1561-1573.
2. Antwi-Boasiako C, Dankwah GB, Aryee R, Heyfron-Benjamin C, Dankor ES & Campbell AD. Oxidative Profile of Patients with Sickle Cell Disease. *Medical Sciences* 2019; 7 (2): 17.
3. Edwards O, Burris A, Lua J, Wilkie DJ, Ezenwa MO, & Doré S. Influence of Haptoglobin Polymorphism on Stroke in Sickle Cell Disease Patients. *Genes* 2022. 13(1): 144.
4. Vona R, Sponsi NM, Mattia L, Gambardella L, Straface E & Pietraforte D. Sickle Cell Disease: Role of Oxidative Stress and Antioxidant Therapy. *Antioxidant* 2021; 10(2): 296.
5. Afolayan JA, Adekile AD & Ogunrinde GO. Serum malondialdehyde and total antioxidant status in adult sickle cell disease patients in steady state. *African Health Sciences* 2019; 19(3): 2649-2656.
6. Dalle-Donne, I, Rossi R, Colombo R, Giustarini, D., & Milzani, A. Biomarkers of oxidative damage in human disease. *Clinical chemistry*. 2006; 52(4): 601-623.
7. Baliga S, Chaudhary M, Bhansali P, Agrawal A, Gundawar S. Estimation of MDA levels in serum and saliva of children affected with SCA. *J indian Soc Pedod Prev Dent*. 2018; 36(1):43-47
8. Atiku SM, Loise N, Kasozi DM. Severe oxidative stress in SCD patients with uncomplicated plasmodium falciparum malaria in kampala Uganda. *BMC infect Dis* 2019; 19: 600.
9. Erhabor O, Jiya N, Abubakar M, Usman S. Some antioxidant enzymes among children with Sickle Cell Disease attending Usmanu Danfodio University teaching Hospital Sokoto, North Western Nigeria. *Journal of blood diseases* 2019; 9:60-76.
10. Poli, G., Leonarduzzi, G., Biasi, F., & Chiarpotto, E. (2004). Oxidative stress and cell signalling. *Current medicinal chemistry*, 11(9), 1163-1182.
11. Kaufman DP, Khattar J & Lappin SL. Physiology, fetal hemoglobin. *StatPearls Publishing* 2023.
12. Collela, MP & Traina F. Fetal haemoglobin and hemolysis markers in sickle cell anemia. *Brazilian Journal of Hematology and Hemotherapy* 2015; 37 (3):143-9
13. Crossley M, Christakopoulos GE & Weiss MJ. Effective therapies for sickle cell disease: are we there yet? *Trends Genetics* 2022;38(12):1284-1298

14. Egesa WI, Nakalema G, Waibi WM, Turyasiima M, Amuje E, Kiconco G, *et al.* Sickle Cell Disease in Children and Adolescents: A Review of the Historical, Clinical, and Public Health Perspective of Sub-Saharan Africa and Beyond. *International Journal of Pediatrics*, 2022; 8 :3885979.
15. Dogonzo IY, Ekoh OC and Enewor TN. Under reported potentials of low foetal haemoglobin in sickle cell disease. *Int J Blood Res Disord* 2022; 9: 080.
16. Akinsheye I, Alsultan A, Solovieff N, Ngo D, Baldwin CT, Sebastiani P, Chui DH, Steinberg MH. *Blood* 2011;118 (1):19-27
17. Sales RR, Nogueira BL, Tosatti JAG, Gomes KB & Luizon MR. Do genetic polymorphisms affect fetal hemoglobin (HbF) levels in patients with sickle cell anemia treated with hydroxyurea? A systematic review and pathway analysis. *Frontiers in Pharmacology* 2022; 12: 779497
18. Olaniyi JA, Arinola OG, & Odetunde AB. Foetal haemoglobin (HbF) status in adult sickle cell anaemia patients in Ibadan, Nigeria. *Annals of Ibadan Postgraduate Medicine* 2010; 8(1): 30-33.
19. Nur E, Biemond BJ, Otten HM, Brandjes DP, Schnog JJB & CURAMA Study Group. Oxidative stress in sickle cell disease; pathophysiology and potential implications for disease management. *American journal of hematology* 2011; 86(6): 484-489.
20. Nader E, Grau M, Fort R, Collins B, Cannas G, Gauthier A. & Connes P. Hydroxyurea therapy modulates sickle cell anemia red blood cell physiology: Impact on RBC deformability, oxidative stress, nitrite levels and nitric oxide synthase signalling pathway. *Nitric Oxide* 2018; 81: 28-35
21. Okorie CP, Nwagha T and Ejezie F. Assessment of Some Indicators of Oxidative Stress in Nigerian Sickle Cell Anemic Patients. *Ann Afr Med.* 2018; 17(1): 11–16.
22. Vona, R, Sposi NM, Mattia L, Gambardella L, Straface E, Pietraforte D. Sickle Cell Disease: Role of Oxidative Stress and Antioxidant Therapy. *Antioxidants* 2021; 2(10): 296.
23. Biswal S, Rizwan H, Pal S, Sabnam S, Parida P, & Pal A. Oxidative stress, antioxidant capacity, biomolecule damage, and inflammation symptoms of sickle cell disease in children. *Hematology* 2019; 24(1): 1-9.
24. Moreira JA, Laurentino MR, Machado RP, Barbosa MC, Goncalves RP, Mota AM *et al.* Pattern of haemolysis parameters and association with fetal hemoglobin in sickle cell anemia patients in steady state. *Brazilian Journal of Hematology and Hemotherapy* 2015; 37(3): 167-171.
25. Lia B, Zhua X, Wardb CM, Starlard-Davenport A, Takezakia M, Berryd A, *et al.* MIR-144-mediated NRF2 gene silencing inhibits fetal hemoglobin expression in sickle cell disease. *Experimental Hematology* 2019;70: 85–96.e5

26. Zhu X, Oseghale AR, Nicole LH, Li B. and Pace BS. Mechanisms of NRF2 activation to mediate fetal haemoglobin induction and protection against oxidative stress in sickle cell disease. *Experimental Biology and Medicine* 2019; 244 (2): 171–182

UNDER PEER REVIEW